Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers

Area of Science:

• Oncology
• Epigenetics
• Cancer Biology

Background:

• Castration-resistant prostate cancer (CRPC) poses a significant clinical challenge due to the development of treatment resistance.
• Epigenetic dysregulation, including alterations in histone modifications, is a key mechanism driving CRPC progression and therapeutic resistance.

Purpose of the Study:

• To investigate the therapeutic potential of simultaneously targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) in CRPC.
• To determine if combined EZH2 and HDAC inhibition can overcome resistance to standard and epigenetic therapies in CRPC models.

Main Methods:

• Utilized preclinical models of CRPC to assess the efficacy of combined EZH2 and HDAC inhibition.
• Evaluated the impact of dual-target therapy on cancer cell proliferation, apoptosis, and gene expression profiles related to epigenetic regulation.

Main Results:

• Combined targeting of EZH2 and HDACs demonstrated significant anti-tumor activity in CRPC models.
• The dual-target therapy sensitized CRPC cells to both epigenetic agents and conventional chemotherapies.
• Restoration of gene expression patterns associated with therapeutic sensitivity was observed.

Conclusions:

• Simultaneous inhibition of EZH2 and HDACs represents a viable therapeutic strategy to overcome castration-resistant prostate cancer.
• This combined epigenetic approach may re-sensitize resistant prostate cancer to existing treatment modalities.
• Further clinical investigation is warranted to translate these findings into patient benefit.